#hepatitis — Thursday, January 22, 2026 (1 items)
| 0 | ℹ |
A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D.
(nejm.org)
|
New England Journal of Medicine 2026-01-22 | #infection #immunotherapy #hepatitis #virologic |